Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Gap Down - Time to Sell?

Key Points

• Sino Biopharmaceutical shares experienced a gap down, opening at $0.86 after a previous close of $0.91.
• The company's 50-day moving average is $1.04, while the 200-day moving average is $0.78, indicating a potential declining trend.
• Sino Biopharmaceutical operates as a pharmaceutical conglomerate in China, focusing on oncology medicines, liver disease medications, and respiratory system medicines.

Sino Biopharmaceutical (OTCMKTS:SBMFF - ) gapped down prior to trading on Thursday . The stock had previously closed at $0.91, but opened at $0.86. Sino Biopharmaceutical shares last traded at $0.86, with a volume of 300 shares changing hands.

Sino Biopharmaceutical Price Performance

The stock has a 50-day moving average of $1.04 and a 200 day moving average of $0.78.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.